Pharma stock jumps 7% after it secures patent for diabetic neuropathic painPharma stock jumps 7% after it secures patent for diabetic neuropathic pain

Introduction:

Pharma stock has gained attention after receiving an Indian patent for its novel topical formulation, Pregabalin Gel 8%. This innovation strengthens the company’s position in diabetic neuropathic pain treatment, marking a major step in its pharmaceutical R&D leadership.

Share Price movement of Lyka Labs:

On April 8, 2025, Lyka Labs Limited opened at ₹102.33, reaching a high of ₹112.84 up 7% from the previous close of ₹101.30 and a low of ₹102.33. The stock is currently trading at ₹107.00, with a market cap of ₹381.88 Crores.

Lyka Labs secures patent:

Lyka Labs Limited has received an Indian patent for the latest topical drug formulation, Pregabalin Gel 8%, which is valid till 2043. This is one more step in confirming the company’s leadership in the development of topical drug solutions for chronic diabetic neuropathic pain in India.

Pregabalin Gel 8% was approved by CDSCO in October 2024 and was launched in December 2024 by Torrent, Intas, and Zuventus under a P2P license. This is the first countrywide product to come to the market. May I also add that this is a unique product; its pain relief is more localized and there are fewer systemic sides.

The study has confirmed the safety and efficacy of Pregabalin Gel 8%. The patent has been received by Lyka Labs. It makes their IP portfolio stronger. The company offers the most innovative and effective therapy for people with neuropathic pain in India.

Also Read: Hotel stock jumps after company signs new property in Darjeeling, West Bengal

Recent news About Lyka Labs:

The company held a board meeting on March 4, 2025, to discuss and approve various matters, including financial results and other strategic decisions.

Stock performance of Lyka Labs for Period of 1 week, 6 months and 1 year:

Lyka Labs stock showed a weak trend, declining by 1.42% over the past week. In the last six months, it dropped significantly by 28.1%. Over the one-year period, the stock posted a negative return of 19.2%, reflecting continued underperformance.

Also Read: Textile stock in focus after company to propose bonus issue

Shareholding pattern of Lyka Labs:

All values in %	Dec-24	Sep-24	Jun-24
Promoters	58.1	58.1	58.1
FII	0.15	0.15	0.15
DII	0.66	0.66	0.75
Retail & others	41.07	41.08	40.99

About Lyka Labs:

Lyka Labs Limited (NSE: LYKALABS) is a pharmaceutical company engaged in the development, manufacturing, and marketing of specialty formulations. It focuses on innovative drug delivery systems, catering to therapeutic areas like dermatology, pain management, and anti-infectives, with operations in both domestic and international markets.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.